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In Brief
Lubman and Fremont describe the
atomic structure of the herpesvirus-
encoded chemokine binding protein R17
alone and in complex with a high-affinity
ligand, CCL3. The study offers novel
insights into the conserved and unique
mechanisms that different pathogens use
to undermine host chemokine signaling
networks.
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A wide variety of pathogens targets chemokine
signaling networks in order to disrupt host immune
surveillance and defense. Here, we report a struc-
tural and mutational analysis of rodent herpesvirus
Peru encoded R17, a potent chemokine inhibitor
that sequesters CC and C chemokines with high af-
finity. R17 consists of a pair of b-sandwich domains
linked together by a bridging sheet, which form an
acidic binding cleft for the chemokine CCL3 on the
opposite face of a basic surface cluster that binds
glycosaminoglycans. R17 promiscuously engages
chemokines primarily through the same N-loop de-
terminants used for host receptor recognition while
residues located in the chemokine 40s loop drive
kinetically stable complex formation. The core fold
adopted by R17 is unexpectedly similar to that of
the M3 chemokine decoy receptor encoded by
MHV-68, although, strikingly, neither the location of
ligand engagement nor the stoichiometry of binding
is conserved, suggesting that their functions evolved
independently.
INTRODUCTION
Chemokines are a group of small cytokines that orchestrate
host defense against microorganisms in vertebrates (Esche
et al., 2005; Gerard and Rollins, 2001). Pro-inflammatory che-
mokines play an essential role in the clearance of a broad array
of pathogens through the recruitment of effector leukocytes
(Luster, 1998). Chemokines establish gradients through specific
interactions with glycosaminoglycans (GAGs), and direct target
cell migration and activation by binding to G-protein-coupled
chemokine receptors (Allen et al., 2007; Handel et al., 2005).
Chemokine networks are characterized by ligand-receptor pro-
miscuity, antagonistically acting ligands, and non-signaling
decoy receptors (Allen et al., 2007; Fernandez and Lolis,
2002; Handel and Lau, 2004). All chemokines adopt a similar
fold consisting of an extended N terminus followed by a long
flexible loop (N loop), a three-stranded b sheet, and a C-termi-Structure 24nal a helix (Fernandez and Lolis, 2002). The structural deter-
minants of chemokine G-protein-coupled receptor (GPCR)
recognition have recently been illuminated by studies of
CXCR4 in complex with a herpesvirus-encoded chemokine
and CX3CL1 in complex with a herpesvirus-encoded che-
mokine receptor (Burg et al., 2015; Qin et al., 2015). Receptor
activation is thought to occur in several steps whereby initial
binding of the chemokine N loop causes conformational
changes in the receptor, allowing the N-terminal residues of
the chemokine to insert between transmembrane helices of
the GPCR (Kufareva et al., 2015).
Pathogens undermine host chemokine signaling networks
using a number of different strategies. Large DNA viruses,
such as herpes- and poxviruses, encode versions of chemo-
kines, chemokine receptors, and unique soluble chemokine
binding proteins capable of sequestering host chemokines
with distinct specificity (Alcami, 2003; Alcami and Lira, 2010;
Epperson et al., 2012). The first secreted chemokine decoy
receptor was discovered in orthopoxviruses, and it is now es-
tablished that a wide array of chemokine binding proteins are
encoded by poxviruses (Patel et al., 1990; Smith et al., 1997).
Unique chemokine binding proteins had been identified in all
three subfamilies of herpesviruses, with perhaps the best char-
acterized being M3 encoded by mouse gammaherpesvirus 68
(MHV-68) (Heidarieh et al., 2015). Bloodsucking ticks and the
helminth parasite Schistosoma mansoni have also been shown
to produce chemokine binding proteins (Deruaz et al., 2008;
Smith et al., 2005).
We recently discovered a novel chemokine decoy receptor
encoded by rodent herpesvirus Peru (RHVP) (Lubman et al.,
2014). RHVP is a gammaherpesvirus (rhadinovirus)-related to
MHV-68 (Stevenson and Efstathiou, 2005) and Kaposi’s sar-
coma-associated herpesvirus (Lee et al., 2015) that establishes
acute and latent infection in laboratory mice with overt pathol-
ogy evident only in immunocompromised animals (Loh et al.,
2011). We demonstrated that R17 binds all human and murine
CC and C chemokines tested (mCCL2 and hCCL2; mCCL3 and
hCCL3; mCCL4, mCCL5, and hCCL5; mCCL8, mCCL11,
mCCL20, mCCL24, mCCL19, mCCL12, and mXCL1) but not
any of the CXC or CX3C chemokines (mCXCL8, mCXCL10,
mCXCL9, mCXCL2, mCXCL12, mCXCL1, and CX3C). Func-
tionally, recombinant R17 potently inhibits CCL3-driven chemo-
taxis of human peripheral blood mononuclear cells (PBMCs)
and CCL2-driven transmigration of human THP-1 monocytes, 57–69, January 5, 2016 ª2016 Elsevier Ltd All rights reserved 57
Table 1. Crystallographic Data Collection and Refinement Statistics
R17_native R17_KI_derivative 1 R17_KI_derivative 2 R17 (KI_ merged) R17-CCL3 complex
Data Collection
Source APS_23ID ALS 4.2.2 ALS 4.2.2 ALS 4.2.2
Wavelength (A˚) 1.0 1.77 1.77 1.0
Resolution (A˚) 50–1.9 (1.93–1.90) 50–2.64 (2.69–2.64) 50–2.90 (2.94–2.90) 90–2.64 50–3.0 (3.06–3.00)
No. of observations 281,521 685,862 641,455 45,751 826,635
Unique reflections 45,516 17,071 13,291 16,547 26,825
Redundancy 3 (2.8) 13.8 (9.7) 13.8 (12.0) 2.8 (1.0) 4.7 (2.3)
I/sI 20.8 (1.83) 39.04 (3.05) 26.9 (2.4) 17.8 (2.7) 7.4 (1.0)
Rmerge
a 5.2 (65.4) 6.8 (83.1) 11.7 (100) 2.1 (100) 11.2 (100)
Completeness 93.8 (61.2) 99.8 (97.6) 100 (100) 970 (56.8) 100 (64.8)
Space group P212121 P212121 P212121 P212121 I222
Cell dimensions (A˚) 69.5, 75.8, 106.9 69.5, 75.3, 106.1 69.5, 76.0, 107.6 98.4, 109.4, 210.9
Phasing Statistics
No. of iodides (SHELXD) 14
Figure of merit (centric) 0.22
Figure of merit (acentric) 0.27
Phasing resolution 46–3.10
Rcullis 0.79
Refinement Statistics
Resolution (A˚) 50–1.9 50–3.0
(outer shell) (A˚) (1.94–1.89) (3.08–3.0)
No. of reflections/no. in Rfree 39,897/2,024 24,120/1,817
Rcryst (%) 18.44 (22.3) 21.52 (32.9)
Rfree (%) 22.08 (34.2) 27.40 (45.5)
Rmsd bond lengths 0.005 0.003
Rmsd bond angles 0.992 0.462
Ramachandran favored (%) 95.6 94.2
Ramachandran outliers (%) 0.0 0.0
Average B factor 21.65 66.92
PDB ID 4ZKQ 4ZLT
Numbers in parentheses refer to the highest-resolution shell.
aRmerge = SjI  <I>j/S<I>, where I is the intensity of each individual reflection.(Lubman et al., 2014). Our initial studies also revealed that in
addition to chemokines, R17 interacts with cell-surface GAGs
in a process dependent upon two BBXB motifs (where B repre-
sents a basic residue) (Lubman et al., 2014). Taken together,
our results suggest that R17 plays a role in RHVP immune
evasion through targeted sabotage of chemokine-mediated im-
mune surveillance.
To gain insight into the mechanism by which R17 sequesters
chemokines, we determined crystal structures alone and bound
to CCL3. R17 adopts a two-lobed structure that engages the
N-loop region of CCL3 important for recognition by its cognate
receptor—a ‘‘hotspot’’ commonly targeted by other pathogen-
derived chemokine decoy receptors. A unique element of the
R17-CCL3 interaction, however, is the engagement of the 40s-
loop BBXB motif that serves an important role in both receptor
and GAG binding for a number of pro-inflammatory CC chemo-
kines. Gain-of-function mutational analysis was used to estab-
lish that R17 selectively engages this GAG binding determinant
of chemokines to form kinetically long-lived complexes. The58 Structure 24, 57–69, January 5, 2016 ª2016 Elsevier Ltd All rightsstructure of R17 also revealed an unexpected similarity to the
M3 chemokine decoy receptor encoded by MHV-68, although
the chemokine binding locations are completely distinct (Alex-
ander et al., 2002).
RESULTS
Structure Determination of RHVP R17
To enable structural studies, recombinant R17 protein was pu-
rified from 293F cells cultured with kifunensine, an inhibitor of
class I a-mannosidase (Elbein et al., 1991). Before crystalliza-
tion, R17 was treated with Endoglycosidase H (EndoH) to
trim carbohydrate (see Experimental Procedures). The struc-
ture of unligated R17 was determined by iodide single-wave-
length anomalous dispersion (SAD) with sites located by
SHELXD (Sheldrick, 2008), phases estimated using MLPHARE
(Dodson et al., 1997), and density modification using PARROT
(Cowtan, 2010) (Table 1). The initial model of R17 was built us-
ing ARP/wARP (Murshudov et al., 1997), and the final modelreserved
Figure 1. Crystal Structure of RHVP R17
Alone and in Complex with Murine CCL3
(A) Ribbon diagram of apo R17. The N-terminal
domain (NTD), bridging sheet (BS), and C-terminal
domain (CTD) are colored based on secondary
structure: b strands are depicted in green, a heli-
ces in cyan, and connecting loops in brown.
b strands of the NTD are labeled 1–10, BS is
labeled B1–B4, and b strands of the CTD are
labeled A–G. During purification, R17 was treated
with EndoH to remove complex carbohydrates. Of
the three predicted N-linked glycosylation sites,
electron density was visible for the N-glycans
linked to Asn103 and Asn205. N-Acetylglucos-
amine (NAG) followed by a mannose ring was built
only for Asn205 and is shown in stick representa-
tion. Disulfide bonds are shown as sticks and
colored yellow.
(B) Crystal structure of the R17GAG2 in complex
with murine CCL3(D26A) at 3.0 A˚ resolution. R17 is
colored as in (A) while the chemokine is colored
magenta and labeled according to accepted che-
mokine convention. Two NAGs linked to Asn103
and Asn205 are shown in ball-and-stick repre-
sentation.
(C) Displayed in white cartoon are superimposed
free and ligated R17 structures. Conformational
changes in the loops around the chemokine bind-
ing cleft are colored green (free R17) and magenta
(chemokine bound R17). TwoGAGbinding sites on
R17 are located on the opposite surface from
chemokine binding and are circled with blue
dashed lines.
(D) Electrostatic complementarity between R17
and CCL3. The molecular surface is colored as
calculated by APBS (<1 kT in red, 0 kT in white,
and >+1 kT in blue).
See also Figure S1.was produced after numerous rounds of manual building using
Coot (Emsley and Cowtan, 2004) and refinement in Phenix
(Adams et al., 2011). The model spans residues 14–400 of
the mature protein, with GlcNAc linkages to Asn103 and
Asn205 along with 355 water molecules (Table 1 and
Figure 1A).
R17 adopts a two-lobed structure with an N-terminal domain
(NTD) positioned perpendicular to a C-terminal domain (CTD)
linked together by a bridging sheet (BS). The terminal domains
consist of b-sandwich folds decorated by loops and helical
segments, while the BS is composed of four strands packed
with the NTD (residues 190–216 and 233–266) and two strands
inserted into the CTD (residues 218–232) (Figure 1A). The NTD
spans residues 14–187 and is composed of a seven- and
three-stranded sheet (Figure 1A). Three disulfide bonds occur
in the NTD; one pins the end of helix h1 to the end of strand
s10, one bridges the turn at the start of s4, and another links
the end of s4 to the start of s9. The CTD spans residues
285–400 and adopts an approximately I-type immunoglobulin
fold composed of nine b strands and a disulfide linking the
C0 strand with the beginning of the D strand. A long flexible
linker connects the BS and CTD, specifically residues 265–
288, of which residues 267–270 are refined with high B factors.
One disulfide is found within the BS B1-B2 loop while anotherStructure 24joins the end of the flexible BS linker to the A00 strand inserted
into the CTD.
Structural Relatives of R17
We looked for proteins of related structure to R17 using the Dali
server (Holm and Sander, 1995), and remarkably found that the
two closest relatives are both from gammaherpesviruses: M3
encoded by MHV-68 (Z score = 14.1) and GP350 encoded by
Epstein-Barr virus (EBV) (Z score = 8.2). The structures of
R17 and M3 aligned with a root-mean-square deviation
(rmsd) of 4.2 A˚ over 262 residues including five disulfide bonds,
despite displaying only 8% sequence identity (Figures 2A and
2B). While similarities with both terminal domains are readily
apparent, the NTDs of R17 and M3 align best (rmsd = 3.3 A˚
for aligned 150 residues with 11% sequence identity). The
R17 BS architecture between the NTD and CTD is absent in
M3, which instead has a series of large helical loops that deco-
rate the CTD.
The core of the R17 CTD domain also displays structural sim-
ilarity to the second immunoglobulin (Ig) domain of the viral sur-
face glycoprotein GP350 encoded by EBV (rmsd of 2.8 A˚ for 109
aligned residues, with 9% sequence identity). EBV infects B cells
through binding of GP350 to complement receptor 2 (CR2)
(Nemerow et al., 1987) using residues from the N-terminal Ig, 57–69, January 5, 2016 ª2016 Elsevier Ltd All rights reserved 59
Figure 2. Structural Comparison of R17
with M3
(A) Comparison of CCL3 (magenta) bound R17 with
CCL2 (yellow) bound M3 where shared core
secondary structure elements are depicted in
green for R17 and dark blue for M3. Divergent
structural elements are depicted in light gray in
both R17 and M3.
(B) Structure-based sequence alignment of R17
with M3. Secondary structure elements of R17 are
on top while secondary structure elements of M3
are on the bottom. Both are colored as in Figure 1A.
Structurally similar residues are colored gray, while
identical residues are in black. Yellow circles
denote M3 chemokine binding interface residues,
while down-pointing magenta triangles denote R17
chemokine binding interface residues. Residues
buried in the M3 dimer are boxed. BBXB motifs on
R17 are boxed in cyan.
See also Figure S2.domain and the linker connecting the first Ig to the second (Sza-
konyi et al., 2006). We tested the ability of biotinylated R17 to
bind CR2-positive B cells in wild-type versus CR2 knockout
mice (Molina et al., 1996; Wu et al., 2000). No differences in
cell staining were noted (data not shown).
Mutational Analysis Based on M3 Chemokine Binding
Determinants
We attempted to define the chemokine binding site on R17
based on the structural similarity to M3 (Figure S1A) (Alexander
et al., 2002). As opposed to monomeric R17, M3 is an anti-par-
allel homodimer with deep chemokine binding clefts formed
between the NTD and CTD of the opposing monomers. We
reasoned that the loop connecting strands 2b to 3 of R17 is
structurally equivalent to the chemokine binding loop s2b-3
from the NTD of M3. By the same token, the large loop con-
necting strands B3 to B4 in the BS of R17 could mimic the
chemokine binding region in the CTD of M3 (Figure S1A, dotted
circles). To experimentally address our hypothesis, we con-60 Structure 24, 57–69, January 5, 2016 ª2016 Elsevier Ltd All rights reservedstructed two R17 variants: R1765AAAA68
has residues 65LEKE68 of the s2b-3 loop
mutated to Ala and R17D248254 has res-
idues 248 through 254 of the B3-B4 loop
deleted. To our surprise, neither of the
R17 variants had altered binding to two
chemokines we tested, CCL2 and CCL3
(Lubman et al., 2014) (Figure S1B), indi-
cating that ligand engagement is most
likely localized elsewhere on the protein.
Crystal Structure of the R17-CCL3
Complex
To address where chemokines bind
R17 we initiated co-crystallization ex-
periments with CCL3, a chemokine we
previously had shown binds the decoy
receptor with an exceptionally long ki-
netic half-life leading to the potent inhibi-tion of PBMC transmigration (Lubman et al., 2014). Diffraction
quality crystals were obtained using a CCL3 mutant (D26A) re-
ported to reduce aggregation (Czaplewski et al., 1999) and an
R17GAG2 variant that could no longer interact with cell surfaces
due to the mutation of residues 333KGRRK337 to 333DGEED337.
The structure of the complex was solved by molecular re-
placement with a final atomic model refined to 3.0 A˚ resolution
(Table 1 and Figure 1B). Each asymmetric unit contained two
R17GAG2-CCL3 complexes, with two GlcNAc linkages to
Asn103 and Asn205 of R17 in chain A and a single GlcNAc
linkage to Asn205 built for chain B. Using multi-angle static light
scattering we determined that R17 binds CCL3 with 1:1 sto-
ichiometry, suggesting that additional lattice interactions
observed in the crystal structure are not functionally relevant
(Figure S2).
The primary structural element used by R17 to create a che-
mokine binding platform is the flexible linker that connects the
BS of R17 with the CTD and forms a hydrophobic cavity
between the two b sandwiches. While this region is not well
Figure 3. Experimental Assessment of Crys-
tallographic Observations
(A) Structure of the R17-CCL3 complex where
chemokine is in electrostatic surface repre-
sentation. Inset shows a part of the linker region
connecting BS and CTD domains. Residues
266DSGSE270 were mutated 266NAGAQ270.
(B) SPR analysis of mCCL2 and mCCL3 binding to
the R17 266NAGAQ270 mutant immobilized to a
CM5 chip. Shown are response curves for a typical
chemokine titration. The experimental curves were
globally fit using a 1:1 mass transport model to
determine the kinetic KD and half-life (t1/2) pre-
sented above each sensorgram. Values for KD are
means of three independent experiments where
KD = kd/ka and t1/2 = 0.693/kd. wt, wild-type; mut,
mutant.ordered in the crystal structure of the unligated R17, it be-
comes partially ordered upon ligand binding (Figure 1C). There
are 31 residues from CCL3 and 46 residues from R17 at the
R17-CCL3 interface, leading to 2,700 A˚2 of buried solvent-
accessible surface area (1,385 A˚2 buried for CCL3 and
1,298 A˚2 buried for R17). The shape complementarity at the
R17-CCL3 interface is calculated to be Sc = 0.70 (Lawrence
and Colman, 1993). In addition to the linker that connects the
two domains, CCL3 is ‘‘clamped’’ through multiple interactions
with both the BS and CTD. A primary structural element of the
BS used to bind chemokines is the B1-B2 loop. A notable hy-
drophobic pocket is formed by R17 residues Val195, Leu198,
Leu239, and Leu264, which serves to sequester CCL3 Phe13,
a critical residue for GPCR binding (Laurence et al., 2000).
The hydrogen bonds observed between the main chain
carbonyl oxygens of Glu199 and Thr200 in R17 with Ser35 of
CCL3 serve as yet another anchor to the BS of R17. AnotherStructure 24, 57–69, January 5, 201pocket buries Arg45 and Asn46 of the
CCL3 40s-loop BBXB motif, formed
mainly by R17 residues Tyr272, Tyr275,
Trp313, Phe378, and Tyr395. Within this
acidic pocket a prominent salt bridge is
formed between Glu393 of R17 and
Arg45 of CCL3. Arg45 is the first B (basic
residue) of the BBXB GAG binding motif
on CCL3, and was shown to be critical
for the ability of CCL3 to bind heparin
sulfate and the CCR5 receptor (Kim
et al., 2001; Koopmann et al., 1999;
Teng et al., 2008).
Comparison of apo with chemokine
bound R17 points to several conforma-
tional variations associated with ligand
binding (Figure 1C). Significant confor-
mational differences are observed in the
linker region connecting the BS and
CTD that makes numerous chemokine
contacts. Large conformational differ-
ences are also observed in the B1-B2
loop, B3-B4 loop, and CC0 loop of the
CTD, each of which flank the engaged chemokine (Figure 1C).
The fact that R17 uses structurally labile elements to engage
chemokines suggests that structural plasticity may be associ-
ated with its broad ligand binding specificity.
Mutational Analysis of the R17 Chemokine
Recognition Site
To experimentally assess our crystallographic observations, we
mutagenized the linker region of R17 and selectively removed
the negative charge from 266DSGSE270 to 266NAGAQ270. The
resulting R17 variant could no longer bind to CCL2 (concentra-
tion range tested up to 150 nM) and bound to CCL3 with more
than 100-fold (t1/2 = 11 s) faster kinetic off-rate compared with
wild-type R17-CCL3 interactions (Figure 3). Thus, the delete-
rious effects of the linker mutations are more pronounced for
R17-CCL2 interactions. This mutational analysis of R17 estab-
lishes that our structurally defined recognition site for CCL3 is6 ª2016 Elsevier Ltd All rights reserved 61
Figure 4. Analysis of Chemokine Binding
Kinetics
(A) Structure of the R17-CCL3 complex where R17
is in electrostatic surface representation. The inset
shows how Arg45 and Gln46 of CCL3 are buried
into a surface pocket of mixed acidic and hydro-
phobic character. A prominent salt bridge is
observed between Arg45 of CCL3 and R17
Glu393, while the side chain of Asn46 makes a
hydrogen bond with the hydroxyl of R17 Tyr323.
(B) Structure-based sequence alignment of
CC chemokines known to interact with R17 ordered
of according to the kinetic stability (as measured by
t1/2) of the complex they form. Conserved cysteines
are colored red; residues of the BBXB motif in the
40s-loop are boxed; residues of CCL2 mutated to
structurally equivalent residues in CCL3 are colored
cyan. Down-pointing magenta triangles denote
CCL3 side chains beyond Ca that make direct
contact (<4 A˚) with R17 and are conserved in both
R17-CCL3 complexes in the asymmetric unit of the
crystal. Additional residues that lose any solvent-
accessible surface area in either complex are
marked with open black triangles. Note that the re-
combinant CCL3 protein used for co-crystallization
has D26A mutation.
(C) SPR curves showing the effect of chemokine
mutations on binding to R17GAG2 coupled CM5
chip: wild-type mCCL2 (left), mCCL2L46R (right),
mCCL2 K47N (bottom left), and mCCL2L46R K47N
mutant (bottom right). The experimental curves
were globally fit using a 1:1 mass transport model
to determine the kinetic KD and half-life (t1/2) pre-
sented above each sensorgram. Values for KD are
means of three independent experiments where
KD = kd/ka and t1/2 = 0.693/kd.shared by CCL2 and, likely, the additional CC and C chemo-
kines it binds.
R17 Binds Chemokines and Cell-Surface GAGs at Two
Distinct Sites
We previously reported that R17 contains two BBXB motifs
located at distal ends of its linear sequence that allow it to
interact with cell surfaces (Lubman et al., 2014). We hypothe-
sized that cell-surface binding will permit R17 to sequester che-
mokines locally, perhaps at the site of infection. Charge reversal
of either one of these motifs abrogated the ability of R17 to bind
to the surface of Chinese hamster ovary (CHO) cells but did not
compromise its ability to interact with chemokines (Lubman
et al., 2014). The crystal structure of R17 supports our initial ob-
servations and provides insight as to howGAG binding by R17 is
accomplished. Despite being far apart in the linear sequence, the62 Structure 24, 57–69, January 5, 2016 ª2016 Elsevier Ltd All rights reservedtwo BBXB motifs found on R17 are in
physical proximity to one another, coming
together to create a large positively
charged surface patch at the junction of
the NTD and CTD (Figure 1C). These
GAG binding determinants are located
more than 40 A˚ away from the chemokine
binding site on the opposite face of R17
(Figure 1D). Interestingly, no basic clus-ters are located on the surface of M3 (Figure 2B). Mechanisti-
cally, these findings are in agreement that R17, but not M3,
can bind cell surfaces while simultaneously interacting with che-
mokines (Lubman et al., 2014).
Kinetically Stable R17 Interactions Are Imparted by
Chemokine 40s-Loop Residues
Kinetic analysis of R17 binding to different chemokines identified
two types of R17-chemokine interactions. Kinetically stable
complexes were formed with CCL3, CCL4, CCL5, CCL24,
and XCL1 (t1/2 > 1000 s), while significantly faster off rates
were observed for the binding of CCL2, CCL8, CCL9, and
CCL20 (Lubman et al., 2014). To address the structural basis
for these distinct kinetic off rates, we undertook a compar-
ative analysis of R17 binding chemokines in the context of our
R17-CCL3 structure (Figure 4A). The alignment of characterized
Figure 5. R17 Inhibits CCL2 Interaction with
Cell-Surface GAGs
(A) FACS analysis monitoring the effect of wild-type
R17, R17GAG1, and R17GAG2 on the interaction of
CCL2 with cell-surface GAGs as measured by
changes in mean florescence intensity. 50 nM bio-
tinylated CCL2 was added to CHOK1 cells in the
presence or absence of 100 nM R17GAG1 (orange
line), 100 nM R17GAG2 (red line) or 100 nM wild-type
R17 (blue line). Cell-surface bound CCL2 was
detected with streptavidin PE using FACSCalibur
(BD Biosciences) and data were analyzed with
FlowJo. Representative histogram plot shows inhi-
bition of CCL2-GAG interactions by R17GAG1 and
R17GAG2.
(B) R17 competes with soluble heparin sulfate for
chemokine binding. R17GAG1 and R17GAG2 were immobilized to a CM5 chip andmCCL2was injected at a concentration of 100 nM, alone or in combination with the
indicated increasing concentrations of heparin sulfate (0, 50 nM, 500 nM, 1 mM, 5 mM, and 10 mM). Error bars represent the SE of three independent experiments.chemokines suggested to us that kinetic stability of the R17-
CCL3 complex might be regulated by basic residues in the che-
mokine 40s loop. If true, replacement of structurally equivalent
residues in CCL2 with residues found in CCL3’s 40s loop could
extend the kinetic half-life of the R17-CCL2 complex. To test
our hypothesis, we created a CCL2L46RK47N variant (Figure 4B)
and evaluated its binding to an R17-coated CM5 chip (Figure 4C,
bottom right). The surface plasmon resonance (SPR) binding
profile of the CCL2L46RK47N double mutant resembled that of
CCL3, characterized by an apparently slow kinetic on-rate and
a half-life exceeding 15 min (Lubman et al., 2014). To further
dissect the contribution of individual 40s-loop residues to com-
plex stability, we created two additional CCL2 variants:
CCL2L46R and CCL2K47N. We found that the CCL2L46R variant
has a 2-fold longer half-life compared with the wild-type CCL2-
R17 interaction (Figure 4C, top right), while the CCL2K47N mutant
forms a less stable complex with a t1/2 of only 5.5 s (Figure 4C,
bottom left). Thus, the single-site mutations only partially explain
the binding profile of the CCL2L46RK47N variant, which could be
stabilized by energetic coupling at the 40s-loop binding interface
(Lubman and Waksman, 2002).
R17 Can Inhibit Chemokine-GAG Interactions
We next sought to address the question of whether CCL2,
whose GAG binding site is localized outside of the BBXB motif
in the 40s loop, loses its ability to interact with GAGs when
bound to R17. The addition of wild-type R17 results in a dra-
matic increase in CCL2 staining of CHO cells due to the decoy
receptor’s ability to bind cell-surface GAGs and chemokines
simultaneously (Figure 5A) (Lubman et al., 2014). We therefore
mutated the two GAG binding sites on R17 and examined
whether our R17GAG1 and R17GAG2 variants (Lubman et al.,
2014) were capable of disrupting the binding of biotinylated
CCL2 to CHO cells (Figure 5). The addition of either GAG bind-
ing null R17 variant resulted in significantly decreased CCL2
staining. To further examine this issue, we designed an SPR-
based competition experiment whereby a fixed concentration
of CCL2 was complexed with varying amounts of heparin sul-
fate and flown over immobilized R17GAG1 or R17GAG2. We found
that addition of heparin sulfate to 100 nM of CCL2 blocked
R17GAG1 and R17GAG2 interactions in a concentration-depen-
dent manner, with 50% of binding disrupted using 50-foldStructure 24excess of heparin sulfate. Together these experiments indicate
that R17 is capable of disrupting direct chemokine-GAG inter-
actions for chemokines such as CCL2 that employ determi-
nants outside the 40s loop.
DISCUSSION
Parallel Evolution of the R17 and M3 Chemokine Decoy
Receptors
With less than 8% sequence identity, the crystal structure of the
unligated R17 revealed unexpected structural similarity to MHV-
68 encoded M3 (Figure 2A). We thus proceeded to use the crys-
tal structures of M3 bound to CCL2 and XL1 (Alexander et al.,
2002; Alexander-Brett and Fremont, 2007) to assess the chemo-
kine binding site of R17. Two R17 variants were designed and
tested based on structurally equivalent chemokine binding re-
gions in M3, neither of which exhibited perturbed binding to
CCL2 or CCL3 (Figure S1B). We therefore determined the crystal
structure of R17 bound to CCL3, which revealed that the spatial
location of chemokine binding on R17 is completely distinct from
that of M3. In contrast to M3, where two chemokine binding
clefts are formed at the distal ends of an anti-parallel homodimer,
R17 engages chemokines as a monomer primarily using a BS
that is completely absent from M3 and, likely, the related M1
and M4 proteins encoded by MHV-68 as well (Alexander et al.,
2002; Clambey et al., 2000; Evans et al., 2006; O’Flaherty
et al., 2014). Interestingly, the R17 chemokine binding cleft is
located in a structurally analogous position as the M3 dimer
interface (Figure 2). Thus, despite a shared structural scaffold,
the capacity of these two herpesvirus proteins to disrupt che-
mokine function appears to have arisen independently. Never-
theless, the chemistry of each chemokine binding niche is
similar, with primarily hydrophobic residues packing against
the chemokine N loop and acidic residues poised to engage
basic chemokine regions.
Unifying Feature of Chemokine Recognition
Pathogens often employ a general strategy of molecular mimicry
to subvert host defense. To understand how unrelated proteins
encoded by distinct pathogens disrupt chemokine signaling,
we compared the recently solved crystal structures of vMIP-II/
CXCR4 and CX3CL1/US28 (Burg et al., 2015; Qin et al., 2015), 57–69, January 5, 2016 ª2016 Elsevier Ltd All rights reserved 63
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Figure 7. ConservedRecognition of Chemo-
kine Invariant Disulfide
The invariant disulfide bond (Cys12-Cys50/51/52) and
flanking Cys11 of different chemokines are de-
picted in ball-and-stick representation with carbon
colored cyan, nitrogen blue, oxygen red, and sulfur
yellow. Decoy and signaling receptor residues that
engage the chemokine invariant disulfide are de-
picted with carbon green for R17 (PDB: 4ZLT), light
blue for M3 (PDB: 2NZ1), orange for vCCI (PDB:
2FFK), magenta for Evasin-1 (PDB: 3FPT), purple
for CXCR4 (PDB: 4RWS), and pink for US28 (PDB:
4XT3). Conserved hydrogen bonds made with
chemokine main chain atoms flanking the invariant
disulfide are represented by dotted yellow lines.with CC chemokines bound to poxvirus vCCI (Zhang et al.,
2006), tick Evasin-1 (Dias et al., 2009), herpesvirus M3 (Alex-
ander et al., 2002; Alexander-Brett and Fremont, 2007), and
R17 (Figure 6). This comparative analysis of chemokine signaling
and secreted decoy receptors revealed one universal aspect of
recognition: the targeting of the invariant disulfide found in all
four chemokine classes. Indeed, a similar chemical strategy is
used by each chemokine binding protein to engage the disulfide
bridge and flankingmain chain. CXCR4, US28, M3, and Evasin-1
all use a Pro residue to contact the disulfide while R17 and vCCI
employ Ile. The backbone conformation surrounding the
invariant disulfide is also highly conserved in these structures,
where the main chain carbonyl of Cys11 serves as hydrogen
bond acceptor and the amide of Cys50, Cys51, or Cys52 serves
as a hydrogen bond donor. In addition, all of the receptors
employ an extended b strand to make these contacts, with all
but R17 oriented in an anti-parallel configuration. Thus, it ap-
pears that many pathogen-encoded chemokine decoys mimic
precisely the same structural and chemical environment as
GPCRs to engage chemokines. Since the invariant disulfide is
present in all four chemokine classes, this unifying aspect of che-
mokine recognition could potentially be exploited for the design
of small-molecule inhibitors.
Promiscuous versus Chaste Chemokine Engagement
The chemokine signaling network employs approximately 50
chemokines and 20 GPCRs, with chemokines activating a select
few receptors in a class-specific fashion. In contrast, many of the
characterized pathogen-encoded decoy receptors bind a broad
spectrum of different chemokines frommultiple chemokine fam-
ilies. For example, M3 is able to bind chemokines from all four
classes (van Berkel et al., 2000), R17 interacts with the CC andFigure 6. Comparison of the Chemokine Binding by Four Pathogen-Derived and Two Host Receptors
Structures of R17 (PDB: 4ZLT), M3 (PDB: 2NZ1), vCCI (PDB: 2FFK), Evasin-1 (PDB: 3FPT), CXCR4 (PDB: 4RWS), and US28 (PDB: 4XT3) in complex with differen
chemokines were superimposed with all chemokines displayed in the same orientation. Displayed at far left are chemokine bound complexes where pathogen
derived decoys and GPCRs are shown in worm diagramwhile chemokines are shown in surface representation. Depicted in the middle are worm diagrams of the
complexes highlighting the chemokine fold and receptor contact regions. Diagrams on the right are shown to highlight chemokine surface regions engaged by
individual receptor determinants. Chemokine residues making direct contact (<4.0 A˚) are labeled in magenta. Additional interfacial residues that lose solvent
accessible surface area in the complex are colored pink.
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fC family of chemokines, and vCCI broadly
recognizes CC and some CXC chemo-
kines (Graham et al., 1997). The excep-tions include the tick Evasins (Deruaz et al., 2008; Frauenschuh
et al., 2007) and HCMV-encoded pU21.5 (Wang et al., 2004
that exhibit chemokine-selective binding profiles. Structura
comparison of four pathogen-encoded chemokine decoys re-
veals that while they all extensively engage the chemokine N
loop, only Evasin-1 engages the N term of CCL3 (Figure 7)
Consistent with this observation, the N termini of chemokines
are thought to be responsible for specific receptor activation
(Clark-Lewis et al., 1995). Indeed, truncations or mutations in
the N termini of chemokines generally lead to a loss in agonis
activity, although receptor binding affinity can be maintained
(Pease et al., 1998). Thus, it appears that R17 along with M3
and vCCI achieve promiscuity by making extensive interactions
with the invariant disulfide and N-loop regions of chemokines
while the N-term region important for chemokine recepto
specificity is ignored. On the other hand, Evasin-1 exclusively in-
teracts with CCL3 and CCL4 perhaps by virtue of extensive
N-term engagement (Dias et al., 2009), a trait shared by GPCR
chemokine receptors (Burg et al., 2015; Qin et al., 2015).
Roles of GAG Binding Determinants
R17 broadly binds CC and C chemokines with nanomolar affin-
ities, but SPR studies indicate that only a subset (CCL3, CCL4
CCL5, CCL24, and XCL1) form kinetically stable complexes
with apparent half-lives exceeding 1 hr (Lubman et al., 2014)
While these chemokines serve to recruit a wide array of immune
cells during viral infection, what they share in common is a GAG
binding BBXB motif in their 40s loop. To examine the role o
these residues in R17 binding we created a CCL2 variant with
the same BBXB motif as found in the 40s loop of CCL3
(KRNR). Strikingly, the mutant CCL2 was endowed with an
extremely long half-life when bound to R17. Thus, R17 appearst
-
-
to target chemokine 40s-loop BBXB motifs to drive extremely
stable complex formation.
Studies of MHV-68-encoded M3 indicate that it potently dis-
rupts chemokine-GAG interactions, and thereby decoy receptor
complexes are likely trafficked away from infected cells (Alex-
ander-Brett and Fremont, 2007). A unique functional element
of R17 is the capacity to engage cell-surface GAGs using two
of its own BBXB motifs positioned distal from the chemokine
binding site. There are no similar basic patches on the surface
of M3, and no functional evidence of M3 cell-surface interactions
has been reported. R17 is most likely positioned in the local
extracellular matrix during infection where it can sequester in-
flammatory chemokines, rendering them inactive. We anticipate
that fluid-phase chemokines would readily bind R17, while GAG
associated chemokines, such as CCL2, would likely need to
dissociate before R17 engagement. This unique functional attri-
bute of R17 provides a distinct immune evasion strategy that
may find therapeutic application in caseswhere localized disrup-
tion of chemokine signaling networks is preferred over systemic
disruption, such as allograft rejection (Proudfoot et al., 2015).
Conclusions
A recurrent theme among pathogens is the repurposing of struc-
tural scaffoldings to facilitate the evasion of host immune de-
fense. For example, viruses use the major histocompatibility
complex (MHC) fold to engage natural killer (NK) cell receptors
to protect infected cells from NK cell-mediated cytotoxicity
(Krmpotic et al., 2005). Still other viruses employ the MHC fold
to, for example, prevent NKG2D ligand-surface expression or
competitively block tumor necrosis factor ligand-receptor inter-
actions (Lodoen et al., 2004; Wang et al., 2012; Zhi et al., 2010).
Thus, it is not particularly surprising that RHVP employs a protein
of similar structure as MHV-68 M3 to block chemokine signaling
networks. What is surprising, however, is that R17 has in parallel
developed the capacity to sequester chemokines using determi-
nants completely distinct from those employed by M3.
EXPERIMENTAL PROCEDURES
Mammalian Production of RHVP R17 and R17GAG2
The cloning, expression, and purification of wild-type R17 and its variants has
been described in Lubman et al. (2014). For crystallization, we employed an
alternative version of the published protocol developed to minimize the
amount of N-linked carbohydrate (Chang et al., 2007). This involved expres-
sion of both R17 and R17GAG2mutant inmedium containing 1mMof the glyco-
sylation processing inhibitor kifunensine. The culture medium was collected
10 days after transfection and was purified using Ni-agarose beads (Qiagen).
The eluted protein was buffer exchanged into 50 mM HEPES (pH 7.5) and
600 mM NaCl, and incubated at room temperature overnight with EndoHf
(3000 U of EndoH for 1 mg of protein) (New England Biolabs). The digested ma-
terial was passed over an amylose column to remove the EndoHf/maltose-
binding protein fusion, followed by size-exclusion chromatography (SEC) on
a HiLoaD 26/60 Superdex 200pg column (GE Healthcare). For purification of
the wild-type R17, the NaCl concentration was maintained at 600 mM
throughout purification and crystallization. For the R17GAG2 variant, the NaCl
concentration was maintained at 150 mM for subsequent co-purification
with CCL3 (see below).
Escherichia coli Production of Murine CCL3(D26A)
The gene encoding the mature form of murine CCL3 with optimization for
E. coli codon usage was cloned into a pET28A vector (Novogen, EMD Biosci-
ences) using NheI and BamHI restriction sites. The D26A mutant was gener-66 Structure 24, 57–69, January 5, 2016 ª2016 Elsevier Ltd All rightsated by site-directed mutagenesis (Agilent Biotechnologies). The CCL3(D26A)
mutant was expressed in E. coli BL21(DE3) cells, and protein production was
induced using 1mM isopropyl b-D-1-thiogalactopyranoside. CCL3(D26A) par-
titioned into the inclusion body fraction and was refolded using the arginine
oxidative refolding method (Nelson et al., 2014). In brief, a 400-ml volume of
arginine refolding buffer (400 mM L-arginine, 100 mM Tris [pH 8.5], 5 mM
reduced glutathione, 0.5 mM oxidized glutathione, and 0.2 mM PMSF) was
prepared. Into this buffer, four injections of 500 ml of solubilized inclusion
body were made over the course of 2 hr (0, 30 min, 60 min, and 120 min).
The refolding buffer was then allowed to stir slowly overnight at 4C. The
following day the protein was filtered, concentrated using a YM-10 (10-kDa
cutoff) filter membrane (Millipore) to a volume of 2 ml, and purified with SEC
using a High Load 16/60 Superdex S75 prep grade column (GE Healthcare).
Crystallization and Structure Determination of R17
R17 was prepared for crystallization by SEC purification in buffer containing
25 mM HEPES (pH 7.5), 600 mM NaCl, and 0.01% Na azide. R17 was then
concentrated to 22 mg/ml and used to set up crystallization trials by
hanging-drop vapor diffusion. Crystals of R17 were obtained in 18%–25%
polyethylene glycol (PEG) 550MME and 100 mM Tris-HCl (pH 8.5) in space
group P212121 (a = 69.561 A˚, b = 75.835 A˚, c = 106.985 A˚) with one molecule
in the asymmetric unit. Crystals were soaked for up to 5 min into a solution
similar to the precipitant solution, but supplemented with 25–250 mM of KI.
Diffraction data for several iodide derivatives were collected at the Advanced
Light Source (ALS) beamline 4.2.2 (Lawrence Berkeley Laboratories) at a
wavelength of 1.77 A˚ (iodide edge) at 100 K with a CCD detector. 360 of
data were collected for all datasets to maximize the multiplicity of the data
(Cianci et al., 2008; Yogavel et al., 2007, 2009), which lowered the error in
the measurement of Bijvoet pairs and thereby increased the accuracy of the
anomalous signal (Schneider and Sheldrick, 2002). Individual iodide derivative
datasets were processed, indexed, and scaled using HKL3000 (Minor et al.,
2006). Anomalous signal from individual datasets was not sufficient for suc-
cessful structure determination. However, merging of two iodide derivative da-
tasets with the ratio of anomalous signal defined at 0.2 allowed SHELDX to find
14 iodide sites, and subsequent SAD phase calculation led to interpretable
experimental electron density maps. ARP/wARP was used to trace over
85% of the model into experimental density and an initial 2.7-A˚ model was
refined to Rwork = 37.16% and Rfree = 46.01%. The 2.7-A˚ model was used as
a search model for molecular replacement of the 1.9-A˚ native dataset
collected at Advanced Photon Source (APS) beamline 23-ID-D. After several
rounds of manual model building using Coot, Phenix (Adams et al., 2011)
was used to refine the R17 structure to a final Rwork of 18.4% and Rfree of
22.08%. The final R17 model contains mature residues 14–400, two Asn-
GlcNAc linkages, and 355 water molecules.
Crystallization and Structure Determination of the R17GAG2/CCL3
Complex
The mouse CCL3 variant (D26A) was produced in E. coli and harbors the mu-
tation D26A. The purification of the R17GAG2 variant is described in the previ-
ous section. The two proteins were mixed in a 1:5 molar ratio of R17 to CCL3.
The 1:1 complex was purified using SEC on the HiLoaD 26/60 Superdex 200pg
column (GE Healthcare). Crystals of the R17GAG2/CCL3 complex at 60 mg/ml
were grown using 22% PEG 3350 and 0.4 M Mg nitrate. Crystals of the com-
plex belong to the I222 space group, with two molecules of R17GAG2 and two
molecules of CCL3(D26A) in the asymmetric unit. Native data were collected at
the ALS beamline 4.2.2 (Lawrence Berkeley Laboratories) at a wavelength of
1 A˚ at 100 K with a CCD detector. The structure of R17 alone and human
CCL3 (PDB: 2X69) was used to solve the structure of the complex bymolecular
replacement using Phaser within Phenix (Adams et al., 2011). The final model
has an R value of 21.52% and Rfree of 27.40%. The refined atomic model of
R17GAG2/CCL3(D26A) comprises residues 18–400 chain A/chain B of R17
and residues 7–68 chain D/chain E of CCL3 along with two N-linked glycosyl-
ation sites for each R17 chain. Due to poor electron density, residues 249–254
of chain A and 247–254 of chain B were not included in the final model. All of
the structural analyses described were done on AD complex.
Flow Cytometry
To evaluate the effect of R17 and its variants on the ability of CCL2 to inter-
act with cell surfaces, chemokines and a negative control protein (MR1)reserved
were non-specifically biotinylated using an EZ-biotin kit (Pierce) with a 2:1
biotin to protein molar ratio, followed by removal of unbound biotin (Thermo
Scientific Zebra Desalting Columns). CHOK1 and CHO745 cells were main-
tained in F-12 media supplemented with 10% fetal calf serum and 1003 peni-
cillin/streptomycin. On the day of the experiment, cells were washed once with
PBS, detached using 0.2% EDTA, and resuspended in staining buffer contain-
ing PBS, 1% BSA, and 2 mM EDTA. Biotinylated CCL2 was added to cells at a
final concentration of 50 nM in the presence or absence of R17GAG1 or
R17GAG2, incubated for 1 hr on ice, washed three times, and detected with
streptavidin PE (Life Technologies) using a FACSCalibur (BD Biosciences).
SPR Binding Analysis
SPR was used to directly measure the affinity and kinetics of chemokine bind-
ing by R17 and its variants, and is described in Lubman et al. (2014). In brief,
R17 was immobilized to on a CM5 chip (GE Healthcare) using standard amine
coupling chemistry (BIAcore Amine coupling kit) to a level of 200–500 response
units for kinetic binding analysis using a BIAcore T-100 biosensor (GE Health-
care). A control flow cell was prepared by coupling a non-chemokine binding
protein R7 or neutravidin to the chip at similar level.
Recombinant Chemokines
Mutagenesis of mouse CCL2 residues Leu46 to Arg and Lys47 to Asn was per-
formed using a Multi-Site Quick Change Mutagenesis Kit (Agilent Technolo-
gies) on the background of the wild-type mouse CCL2 and verified by DNA
sequencing. Murine CCL2, CCL2L46R, CCL2K47N, and CCL2L46R K47N were ex-
pressed in E. coli, refolded from inclusion bodies, and purified as previously
described (Nelson et al., 2014).SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures and can be found with this
article online at http://dx.doi.org/10.1016/j.str.2015.10.018.
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